Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molokini: KPI-121 for RVO or DME
NCT02245516Phase 2Completed
- Sponsor
- KALA BIO
- Start
- Jul 2014
- Primary completion
- Dec 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of loteprednol etabonate ophthalmic gel 0.38% in retinal vein occlusion (RVO) and diabetic macular edema (DME) (2 arms), sponsored by KALA BIO. Primary endpoints: Best Corrected Visual Acuity, Macular Volume and 2 more. Started Jul 2014; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
retinal vein occlusion (RVO)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02245516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245516.